-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
SOLUTIONS
-
Research & Development
-
Real World Evidence
-
Commercialization
-
Safety & Regulatory Compliance
-
Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
- Information Partner Services
- Financial Institutions
- Global Public Health
- Government
- Patient Associations
- Payers
- Providers
THERAPEUTIC AREAS
- Cardiovascular
- Cell and Gene Therapy
- Central Nervous System
- GI & Hepatology
- Infectious Diseases and Vaccines
- Oncology
- Pediatrics
- Rare Diseases
- View All
Impacting People's Lives
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewResearch & Development Quick Links
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWReal World Evidence Quick Links
See markets more clearly. Opportunities more often.
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWCommercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWSafety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWTechnology Quick Links
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
BLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSTHE IQVIA INSTITUTE
An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
FEATURED INNOVATIONS
-
IQVIA Connected Intelligence™
-
IQVIA Healthcare-grade AI™
-
IQVIA AI Assistant
-
Human Data Science Cloud
-
IQVIA Innovation Hub
-
Decentralized Trials
-
Patient Experience Solutions with Apple devices
WHO WE ARE
- Our Story
- Our Impact
- Commitment to Public Health
- Code of Conduct
- Sustainability
- Privacy
- Executive Team
NEWS & RESOURCES
Unlock your potential to drive healthcare forward
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
IQVIA AI is Healthcare-grade AI
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Meet the IQVIA AI Assistant
Your new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.
LEARN MORE
Your healthcare data deserves more than just a cloud.
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
Proven, faster DCT solutions
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
IQVIA Patient Experience Solutions with Apple devices
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREWORKING AT IQVIA
Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORELIFE AT IQVIA
Careers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE
WE’RE HIRING
"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSBlog
Migraine market continues exponential growth
Apr 05, 2022
The launch and continued strong uptake of biologic calcitonin gene-related peptide (CGRP) monoclonal antibodies for the preventative treatment of migraine in 2019 has transformed the sales outlook for this disease. However, additional flexibility in route of administration for this mechanism has created new pipeline treatments and opens a new commercial avenue for use in both prevention and acute migraine attacks for existing and novel migraine treatments. Alongside the continued uptake of injectable biologics, this drives the high projected growth in sales for this disease over the next 10 years, and positions migraine as the 3rd highest selling disease in the CNS disease area by 2026.
Migraine is a neurological disease that causes a variety of symptoms, such as throbbing, pulsing headache, nausea, and sensitivity to light, sound, and activity. It may last at least four hours but can also persist for days for some sufferers1. According to the 2019 Global Burden of Disease study, migraine continues to be the second highest cause of global disability, and is first among young women 2. Migraine has a wide global distribution: it can be found in all continents, but with a prevalence that varies across geographic regions, higher in North, South America and Europe, intermediate in Asia, and lowest in Africa 3.
There is no complete cure for migraine since its pathophysiology has yet to be fully understood. Historically, there have been two ways to approach the treatment of migraine headache4:
- relieve the symptoms during the attacks
- prevent the attacks, including non-pharmacological interventions
Prior to 2019 most pharmacological interventions treated the symptoms of an attack at the point of onset, and global sales for this disease were estimated at $2.2bn (IQVIA Forecast Link). A proportion of suffers experience aura as a warning of migraine, so treatment can be taken in a timely manner, although treatment generally consisted of pain relief, triptans or opioids, with little else available if these methods did not provide relief.
However, the launch of calcitonin gene-related peptide (CGRP) monoclonal antibodies in 2019 as preventative treatments has changed the treatment landscape for severe migraine suffers. These treatments are the first to be designed to act on the trigeminal pain system and are considered to be more specific with little or no adverse effects 5. These expensive biologic treatments have also catapulted migraine to the 5th highest sales disease in CNS, with IQVIA Forecast Link forecasts predicting a move to third place by 2026, with global sales of $13.2bn
More recent innovation includes the use of the CGRP mechanism in different delivery forms, specifically nasal delivery which provides a quick entry to the blood stream. This mechanism of action can act as both a preventative and acute treatment. Nasal delivery is not new to the migraine market, with products like nasal triptan treatments readily available for migraine suffers, but flexibility in the route of administration methods for this mechanism has created new pipeline treatments and opens a new commercial avenue for existing and novel migraine treatments. Alongside the continued uptake of injectable biologics, this drives the high projected growth in sales for this disease over the next 10 years.
There are several orally available CGRP inhibitors already on the market (known as gepants), but few for the prevention of migraine. Currently there is only one orally available gepant with both an acute label, and an expanded prevention label. Recently launched atogepant An orally available CGRP inhibitor was approved just for preventative treatment of episodic migraine. This preventative indication means a long-term course of treatment, rather than a short-term acute treatment , opening a much larger sales opportunity.
Novel pipeline candidate zavegepant, is looking to be used in both patient groups of prevention and acute treatment, a sure way to maximize commercial opportunities.
Other treatments in the pipeline also focus on new formulations and routes of administration, but it is the acute and preventative label that will provide the commercial opportunity in this crowded market.
A comparison of sales verses drug-treated patient numbers from IQVIA’s Forecast Link and Patient Link shows the huge number of patients receiving small molecule, likely acute, generic, inexpensive treatments. Sales however are driven more by the injectable biologic treatments which by IQVIA’s Patient Link calculations are, globally, only used in 2% of drug-treated migraine patients.
- https://my.clevelandclinic.org/health/diseases/5005-migraine-headaches
- Steiner et al., 2020 https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-020-01208-0
- Vigano et al., 2019 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6519367/
- https://www.ninds.nih.gov/Disorders/All-Disorders/Migraine-Information-Page
- Edvinsson, 2019 https://pubmed.ncbi.nlm.nih.gov/30725283/
IQVIA Forecast Link provides regularly updated and fully segmentable sales and volume forecasts across 10,000 products, 600 diseases and 73 countries. Gain insights into current and future market landscapes and power your strategic decision making via this single easy-to-use platform providing unrivalled breadth of coverage.
To learn more, please view the Forecast Link video at https://www.iqvia.com/library/videos/iqvia-forecast-link